雌孕激素及HER-2受体表达在乳腺癌进展中的差异性  

Difference of Estrogen Progesterone and HER-2 Receptor Expressions during the Progression of Breast Cancer

作　　者：厉飞[1] 张喜平[2] 陈道宝[2] 

机构地区：[1]浙江中医药大学第一临床医学院,中医学七年制杭州310053 [2]浙江省肿瘤医院乳腺肿瘤外科

出　　处：《浙江中医药大学学报》2013年第3期356-359,共4页Journal of Zhejiang Chinese Medical University

基　　金：浙江省151人才基金资助(2010382)~~

摘　　要：[目的]探讨雌孕激素及HER-2受体在乳腺癌进展中表达的差异性。[方法]通过查找文献,搜集相关论文并对其进行分析和总结。[结果]文献报道显示乳腺癌的ER、PR、HER-2受体表达可随着肿瘤的进展而发生改变,可因个体差异而发生动态改变,也可以由于前期的治疗而改变。[结论]乳腺癌原发灶和进展期病灶之间的ER、PR及HER-2受体表达存在一定差异性,因此有必要重视并重新评估乳癌患者进展病灶中的雌孕激素及HER-2的受体状况,从而制定更加有效的治疗方案。[Objective} To study the differences of estrogen, progesterone and HER-2 receptor expression during the progression of breast cancer. [Method] By consulting literature, we analyze the relevant papers and summarize them. [Results]The reports we find out show that the ER, PR, HER-2 receptor expression of breast cancer will change as the tumor progresses, it may be because of individual differences or the pre-treatment. [Conclusion] There are certain differences of ER, PR and HER-2 receptor expression in primary tumor and advanced lesions of breast cancer, therefore, we should attach importance to it and reevaluate the ER, PR and HER-2 receptor status in breast cancer in order to make more effective therapeutic schedule.

关 键 词：乳腺肿瘤 ER PR HER-2 

分 类 号：R271[医药卫生—中医妇科学]